[Endothelin receptor blockers--one more agent for the treatment of pulmonary hypertension].
Data on participation of derangements of pulmonary vessel endothelial function in pathogenesis of pulmonary hypertension served as basis for therapeutic use of prostanoids, sildenafil, and endothelin(ET) receptor blockers. A first representative of the latter group - bosentan (nonselective ET-receptor antagonist) has been recently registered as an agent for the treatment of pulmonary hypertension. Bosentan and other ET receptor antagonists has been studied in several trials. Results of these trials are reviewed in this paper which also contains characteristics of main representatives of ET receptor antagonists as well as information on their tolerability and major side effects.